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An Experts Meeting on Lung Cancer and the Use of Erlo-
tinib was held on 10th November 2007, in New York City,
USA. The meeting was organized by ACINDES (Asociación
Civil de Investigación y Desarrollo en Salud [Civil Association
for Health Research and Development]), a private interna-
tional academic institution actively involved in medical
research and the development of educational programs
since 1985.
The meeting brought together a group of distinguished
lung cancer oncologists with the aim of reviewing existing
evidence on the use of erlotinib for the treatment of this
pathology. Dr. Néstor Mendyk was in charge of opening
the event, which was coordinated by the oncology special-
ist Dr. Aldo Castagnari. Also attending the meeting were
Dr. Víctor Lira Puerto, medical oncologist at the ABC Hos-
pital, Mexico City, and, as a special guest, Dr. Nicholas
Thatcher, Professor of Medical Oncology at Manchester
University, UK, who offered lectures with up-dated infor-
mation on the use of erlotinib.
The agenda and the most relevant information were devel-
oped using a series of questions as a guide so that partici-
pating experts could exchange data from their own
experience and published literature. These questions
included addressed the most relevant information on effi-
cacy and safety regarding erlotinib use. This publication is
a most important tool for the Latin America medical com-
munity because it will provide access to a summary of the
lectures and to the most prominent opinions of regional
professionals and experts in the field.
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